JGC
BCYC

J. Goldman & Co’s Bicycle Therapeutics BCYC Stock Holding History

J. Goldman & Co’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-49,944
Closed -$1.06M – 382
2023
Q1 		$1.06M Buy
+49,944
New +$1.25M 0.04% 229

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

J. Goldman & Co's BCYC Position: Q2 2023 in Review

J. Goldman & Co sold out of Bicycle Therapeutics (BCYC) in Q2 2023, closing a stake of 49,944 shares — an estimated $1.06M sold.

J. Goldman & Co first reported a position in BCYC in Q1 2023 and held it in 1 quarter. The position peaked at $1.06M in Q1 2023. 85 funds tracked by Wall St. Rank hold BCYC as of Q2 2023.

  • J. Goldman & Co reported no remaining Bicycle Therapeutics position as of Q2 2023 after selling out during the quarter.
  • J. Goldman & Co sold 49,944 Bicycle Therapeutics shares in Q2 2023, an estimated $1.06M.
  • J. Goldman & Co first reported a position in Bicycle Therapeutics in Q1 2023 and held it in 1 quarter.
  • J. Goldman & Co's Bicycle Therapeutics position peaked at $1.06M in Q1 2023.
  • 85 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.